Key Highlights
- Relmada Therapeutics shares climbed approximately 31% during pre-market hours Monday following two significant company announcements
- Phase 2 interim results for NDV-01, targeting bladder cancer, demonstrated a 76% complete response rate at 12 months
- An oversubscribed private placement worth $160 million closed at $4.75 per share
- The financing round encompasses 29.47 million common shares plus pre-funded warrants for 4.21 million additional shares, with closing scheduled for March 11
- Analyst consensus rates RLMD as Strong Buy with a mean price target of $10.25
Relmada released interim clinical results from the Phase 2 study evaluating NDV-01 for treating high-risk non-muscle invasive bladder cancer (NMIBC). Data revealed a 12-month complete response rate reaching 76%, accompanied by a well-tolerated safety profile. The treatment achieved this response benchmark among the BCG-unresponsive patient subset as well.
Dr. Raj S. Pruthi, MD, serving as Chief Medical Officer of Oncology for Relmada, described the findings as “meaningful clinical validation” for the development program.
Relmada Therapeutics, Inc., RLMD
Management indicated plans to move NDV-01 forward into a registrational Phase 3 program named RESCUE, which will pursue two distinct pathways: one for BCG-unresponsive patients and another for adjuvant intermediate-risk patients. The Phase 3 trials are anticipated to commence during mid-2026.
Private Placement Details
Concurrent with the clinical data release, Relmada disclosed completion of an oversubscribed private placement totaling $160 million.
The financing structure includes 29,474,569 common shares offered at $4.75 per share, alongside pre-funded warrants covering 4,210,527 additional shares priced at $4.749 with an exercise price of $0.001.
Jefferies, Leerink Partners, Piper Sandler, and Mizuho serve as placement agents for the transaction. The funding round expects to finalize on March 11, 2026, pending customary closing conditions.
Relmada designated the capital raised for working capital requirements and continued advancement of research and development initiatives.
The transaction terms include resale registration rights for participating investors. Relmada agreed to maintain timely SEC filing compliance, with liquidated damages structured at 1.0% for each 30-day delay period if filing deadlines lapse, though caps apply.
Share Performance
RLMD traded up 31.01% during Monday’s pre-market session. The shares had recorded a modest increase in Friday’s regular session.
For the year-to-date period, shares remain down 7.87%. Looking at the trailing 12-month timeframe, the stock has delivered gains of 1,536%.
Trading activity intensified dramatically following the announcements. Volume exceeded 7.9 million shares on Monday, substantially higher than the three-month daily average of approximately 570,000 shares.
This volume spike—representing more than 13 times the typical daily activity—underscores the significant market interest generated by both company announcements.
Wall Street analysts currently assign RLMD a Strong Buy consensus rating, reflecting four Buy recommendations published within the most recent three-month period.
The average analyst price target stands at $10.25, implying potential upside of approximately 130% from present trading levels.
